CurrentUnitedHealthcarePolicy DCP045.09

Dental Barrier Membrane Guided Tissue Regeneration

This policy governs the use of resorbable and non-resorbable barrier membranes for guided tissue regeneration (GTR) and guided bone regeneration (GBR) in dental and implant-related procedures and applies to UnitedHealthcare dental benefits.

Policy Summary

PayerUnitedHealthcare

PolicyDental Barrier Membrane Guided Tissue Regeneration

Policy CodePolicy DCP045.09

Change TypeClarified supporting evidence and references

Effective DateMay 1, 2025

Next Review Date

Key ActionObtain prior authorization per member benefit with procedure code(s) and clinical rationale documenting the specific indication and membrane type.

SourceLink

POLICY UPDATE CHANGES

Updated Clinical Evidence and References sections to reflect the most current information.

9listed procedure codes (CDT)

resorbable & non-resorbablemembrane types

intrabony & Class IIprimary indications

hopeless teeth / <2-wallexplicit contraindications

systematic reviews

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Class IIFDA classification

Coverage Criteria

Medically necessary criteria for GTR/GBR

Covered when ALL of the following are met:

Primary indications: Procedure is for intrabony/infrabony vertical defects OR Class II furcation involvements OR in conjunction with bone grafting for ridge preservation, ridge augmentation/reconstruction, implant placement, treatment of peri-implant defects, or to enhance periodontal tissue regeneration and healing for mucogingival defects in conjunction with mucogingival surgeries.

From indications list.

Tooth and patient selection: Tooth must not have a poor or hopeless prognosis; patient must not have uncontrolled underlying medical conditions that impair healing (including but not limited to metabolic, cardiovascular, autoimmune/inflammatory, or genetic conditions affecting collagen synthesis); patient must not be taking medications that negatively affect healing (including but not limited to immunosuppressive agents, corticosteroids, anticoagulants, NSAIDs, or nicotine); patient must be compliant with prior therapies and maintain adequate oral hygiene.

Contraindications and exclusions listed.

Defect morphology: Osseous defects must have suitable morphology for regeneration (not less than two walls and not crater defects); periapical lesions of endodontic origin are excluded unless specific evidence supports benefit on a case-by-case basis.

Osseous defects with <2 walls and crater defects are not indicated.

Clinical evidence-based considerations

Evidence summaries and clinical guidance relevant to coverage determinations

Membrane benefit in one-stage ridge augmentation: For one-stage ridge augmentation and immediate implant placement, randomized trials and pooled analyses report small but statistically significant increases in horizontal bone gain and defect height reduction favoring membrane-covered groups, though heterogeneity is substantial and sample sizes are small.MD: 0.84 mm horizontal gain (two trials); defect height reduction MDs reported

See Jonker et al. and Merli et al. systematic reviews for details

Membrane type differences: Some trials and pooled analyses found non-resorbable ePTFE membranes achieved complete clinical fill of defects more frequently than resorbable PLGA membranes; no consistent differences were observed between ePTFE and resorbable collagen membranes. Heterogeneity is high for cross-linked membranes.odds ratios reported favoring ePTFE in Merli et al.

Merli et al.; Jonker et al.

Coverage for guided tissue regeneration (GTR) / guided bone regeneration (GBR) is limited to situations where patient selection and defect characteristics support a likelihood of biologic benefit. Contraindicated conditions include teeth with a poor or hopeless prognosis, patients with uncontrolled underlying medical conditions that impair healing (metabolic, cardiovascular, autoimmune/inflammatory, or genetic conditions affecting collagen synthesis), individuals taking medications that adversely affect healing (including immunosuppressive agents, corticosteroids, anticoagulants, NSAIDs, and nicotine), and patients who are non‑compliant or have poor oral hygiene. Additionally, osseous defects with less than two walls and crater defects are not appropriate indications for membrane use, and GTR/GBR is not indicated for periapical lesions of endodontic origin.

Systematic reviews and randomized trials report heterogeneous and generally limited evidence across several applications of membranes. For one‑stage ridge augmentation and some immediate implant placement trials there were small mean differences favoring membrane‑covered groups for horizontal bone gain and defect height reduction, but sample sizes were small, heterogeneity was substantial, and follow‑up was short. Evidence was insufficient to determine benefit for two‑stage ridge augmentation, sinus augmentation, ridge preservation, and for treatment of endodontic‑periodontic lesions; systematic reviews conclude that current data do not support definitive conclusions and recommend further well‑designed studies.

Uses not recommended or considered inappropriate include application of GTR/GBR where the tooth prognosis is hopeless, for defects that lack sufficient bony walls (i.e., less than two walls), for crater defects, and for routine management of periapical/endodontic lesions given the lack of demonstrated additional benefit. Clinicians should also avoid membrane procedures in patients with uncontrolled systemic conditions or behaviors that compromise healing, or when patients are non‑compliant with prior therapies.

The policy does not set an absolute blanket 'not medically necessary' designation for every situational use of membranes; instead, it notes that evidence is insufficient to support routine use of membranes for several applications (including two‑stage ridge augmentation, sinus augmentation, ridge preservation, and endodontic‑periodontic lesions) and identifies specific contraindications where the procedure is not appropriate (for example, hopeless teeth and defects with less than two walls). When contraindicated conditions are present, requests are expected to be denied.

Coding

Applicable CDT procedure codesmixed

D6106	Guided tissue regeneration - resorbable barrier, per implant.
D6107	Guided tissue regeneration - non-resorbable barrier, per implant.
D3432	Guided tissue regeneration, resorbable barrier, per site, in conjunction with periradicular surgery.
D4266	Guided tissue regeneration, natural teeth - resorbable barrier, per site.
D4267	Guided tissue regeneration, natural teeth - non-resorbable barrier, per site.
D4286	Removal of non-resorbable barrier.
D7956	Guided tissue regeneration, edentulous area - resorbable barrier, per site.
D7957	Guided tissue regeneration, edentulous area - non-resorbable barrier, per site.

Device/Product codeHCPCS

NPL	FDA product code referenced for barrier membranes (510[k]/PMN lookup).

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required for Listed CDT Codes

Prior authorization may be required per member benefit for the following CDT procedure codes. Providers should verify member-specific benefit coverage and obtain prior authorization when required before scheduling the procedure to avoid claim denials or delays.

Applicable CDT procedure codes: D6106, D6107, D3432, D4266, D4267, D4286, D7956, D7957
Prior authorization required when specified by the member’s benefit plan — check eligibility and benefits and submit the request with supporting documentation

Note

Prior Authorization / Device Code (Informational)

The FDA classifies barrier membranes as Class II devices. For informational purposes, individual product 510(k) premarket notifications can be searched using product code NPL. Device regulatory status does not by itself determine coverage; follow member benefit rules for any device-related prior authorization.

FDA classification: Class II (barrier membranes)
510(k) searches: product code NPL — informational only

Background

Barrier membranes are biomaterials placed to exclude epithelial and connective tissue cells and to maintain a space that supports regeneration of bone, cementum, and the periodontal ligament around teeth or implants. Membranes may be resorbable (for example, collagen or synthetic polyesters) or non‑resorbable (for example, e‑PTFE/d‑PTFE); choice of membrane and procedure should account for defect morphology, patient healing capacity, and device characteristics.

Definitions

Furcation — definition and involvement

DefinitionThe anatomic area of a multirooted tooth where the roots diverge; furcation involvement refers to loss of periodontal support in this area and is graded by extent of bone loss (Grade I–IV).

Clinical significanceFurcation involvement indicates periodontal support loss and affects prognosis and treatment selection; certain grades (III–IV) are associated with poor or hopeless prognosis.

Grading examplesGrade II: instrument enters furcation but not all the way through; Grade III: through-and-through involvement; Grade IV: through-and-through with clinical visibility due to gingival recession.

Guided Tissue Regeneration — definition and purpose

DefinitionA surgical procedure with the goal of achieving new bone, cementum, and periodontal ligament attachment to a periodontally diseased tooth using barrier devices or membranes to provide space maintenance, epithelial exclusion, and wound stabilization (AAP).

Policy Summary

PayerUnitedHealthcare

PolicyDental Barrier Membrane Guided Tissue Regeneration

Policy CodePolicy DCP045.09

Change TypeClarified supporting evidence and references

Effective DateMay 1, 2025

Next Review Date

Key ActionObtain prior authorization per member benefit with procedure code(s) and clinical rationale documenting the specific indication and membrane type.

SourceLink

On This Page

Evidence limitations:

Overall evidence is limited by small trials, short follow-up, and high or unclear risk of bias; therefore definitive clinical value across procedures (including two-stage ridge augmentation, sinus augmentation, and ridge preservation) is uncertain.

majority of included trials at high or unclear risk of bias

Applies to multiple augmentation indications

Endodontic-periodontic lesions: Systematic reviews and a randomized trial show insufficient evidence to support routine benefit of GTR/membranes for endodontic-periodontic (through-and-through or apico-marginal) lesions; one RCT (Parmar et al.) found no difference at 12 months.Parmar RCT N=32; Rosen et al. systematic review N=4 studies

Recommend further research with defined inclusion criteria and 3D imaging

Documentation Required

Required Clinical Indication Documentation

Requests must include documentation that supports the specific clinical indication for guided tissue regeneration (GTR). Submit operative notes, radiographs, and clinical findings that demonstrate the qualifying indication.

Required documentation: clinical notes describing the diagnosis and defect anatomy, periodontal charting, intraoral radiographs or CBCT showing the defect, and operative plan specifying use of membrane (resorbable vs non-resorbable)
Examples of qualifying indications to document: intrabony defects, Class II furcation, ridge preservation/augmentation, peri-implant defects, or adjunct to mucogingival surgery

Denial Risk

Documentation and Contraindications — Denial Risk

Do not request or expect coverage for GTR when contraindications exist or when clinical documentation does not support a qualifying indication. Failure to provide required documentation or presence of contraindicated conditions may result in denial.

Denial risk increases when: inadequate documentation of the defect or indication; documented contraindications are present; defect anatomy is <2-wall or a crater defect; tooth prognosis is poor/hopeless

Primary purposeTo promote regeneration of periodontal tissues (bone, cementum, PDL) at sites of periodontal destruction by excluding undesirable cell types and maintaining space for healing.

AdjunctsTypically uses barrier membranes and may include bone grafting materials to support space maintenance and tissue in-growth.

Ridge Preservation — definition and purpose

DefinitionA surgical procedure aimed at preventing ridge collapse and preserving ridge dimension after tooth extraction, typically done for purposes of implant site development and involving hard and/or soft tissue biomaterials and/or membranes (AAP).

PurposePreserve alveolar ridge dimensions to facilitate future implant placement or restorative needs by minimizing post-extraction bone loss.

Common materialsUses hard/soft tissue biomaterials and membranes (resorbable or non-resorbable) as part of the procedure.

GTR/GBR — combined definition

DefinitionCollective term for surgical techniques that use barrier membranes, often with bone grafts, to direct healing of periodontal and peri-implant tissues by excluding epithelial/connective tissue and maintaining space for regeneration (GTR for teeth; GBR for bone/implant sites).

MechanismBarrier membranes provide epithelial exclusion and space maintenance to allow selective repopulation by bone and periodontal ligament cells, facilitating new attachment and bone fill.

Clinical applicationsIndications include intrabony/infrabony defects, certain Class II furcation involvements, ridge preservation/augmentation, implant placement/peri-implant defects, and select mucogingival procedures when criteria are met.

Resorbable vs non-resorbable membranes — comparison and implications

Resorbable membranesBiodegrade over time (examples: collagen, synthetic polyesters such as PLGA); do not require a second procedure for removal.

Non-resorbable membranesExamples include ePTFE (expanded PTFE); may require removal and in some studies achieved higher rates of complete defect fill compared with some resorbable synthetic membranes.

Clinical implicationsMembrane type influences outcomes and complications: some reviews report greater complete defect fill with non-resorbable ePTFE versus resorbable PLGA, but no difference versus resorbable collagen; membrane use may increase complication rates in certain procedures.

Regulatory noteBarrier membranes are FDA Class II devices; product-specific 510(k)/PMN information can be looked up using product code NPL.